Precision BioSciences, Inc. has reorganised its senior leadership team as the Nasdaq-listed gene-editing developer works to advance two wholly owned clinical-stage programmes through their next data and operational milestones. Alex Kelly will move from chief financial officer into the newly created role of chief operating officer, while Naresh Tanna, currently vice president of investor relations and chief of staff to the chief executive officer, will become chief financial officer from August 1, 2026.
Kelly will oversee what Precision BioSciences described as its key customer-facing functions, while Tanna will assume responsibility for corporate finance, financial reporting and investor relations. Cindy Atwell will continue to direct clinical development for PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, supported by two newly hired physician leaders with infectious disease and muscular dystrophy expertise. Chief Scientific Officer Cassie Gorsuch will now lead all research functions, including clinical-stage translational science and next-generation programmes.
The changes are more significant than their job-title arithmetic might initially suggest. Precision BioSciences is moving from a period dominated by platform development, portfolio prioritisation and regulatory preparation into one requiring simultaneous clinical operations, biomarker interpretation, safety management, medical engagement, investor communication and capital discipline.
The company still has no approved commercial product, and neither of its lead candidates has reached confirmatory development. The reorganisation should therefore not be interpreted as preparation for an imminent product launch. It is better understood as an attempt to establish clearer executive ownership before early clinical findings begin to determine whether the ARCUS platform can translate into credible therapeutic programmes.
Why has Precision BioSciences created a chief operating officer role at this clinical stage?
Moving Alex Kelly from chief financial officer to chief operating officer broadens his remit from financial stewardship into external execution. Precision BioSciences has not explained every function that will report to him, but the phrase “customer-facing functions” suggests a role encompassing important external relationships, potentially including business development, strategic partnerships, investor engagement and other interactions surrounding the company’s clinical programmes.
Kelly’s background makes the appointment less unconventional than it may appear. Before joining Precision BioSciences in 2020, he held corporate affairs, communications, integration and investor-relations positions at companies including Allergan, Actavis and Forest Laboratories. His previous work included supporting corporate transformations and integration programmes associated with major pharmaceutical transactions.
That experience may become increasingly useful as Precision BioSciences seeks to convert scientific progress into institutional credibility. A clinical-stage biotechnology company must communicate across very different audiences, including investigators, regulators, potential partners, investors and patient organisations. Those groups do not evaluate a programme in the same way, and scientific promise does not automatically answer questions about trial feasibility, manufacturing, regulatory strategy or financing.
The creation of the COO role also gives Chief Executive Officer Michael Amoroso a senior executive who can coordinate external and operational priorities while the research and development organisation concentrates on clinical evidence. The practical test will be whether this structure shortens decision-making routes rather than adding another management layer.
How does the new structure divide scientific, development and external execution responsibilities?
The revised structure creates a more visible separation between research, clinical development, external operations and finance. Gorsuch will lead scientific research, translational science and future programmes, while Atwell remains responsible for advancing the two clinical-stage assets. Kelly takes the operating and outward-facing portfolio, and Tanna becomes responsible for finance, reporting and investor relations.
Atwell’s existing remit has extended across clinical, regulatory, translational and programme-management activities, as well as business development and alliance management. She joined Precision BioSciences in 2019 and has worked across pharmaceutical and biotechnology companies including Halozyme Therapeutics, AbbVie and Amylin Pharmaceuticals.
The addition of two physician leaders reporting under Atwell is particularly relevant. Chronic hepatitis B and Duchenne muscular dystrophy require very different clinical-development capabilities. One programme involves repeat lipid nanoparticle administration, virological biomarkers, liver biopsies and a potential future framework for withdrawing background antiviral therapy. The other involves a one-time adeno-associated virus-delivered gene-editing intervention in young children, with immunomodulation, muscle biopsies and long-term safety monitoring.
Specialised medical leadership may therefore be more consequential than the headline executive promotions. Trial expansion often exposes operational problems that do not appear during preclinical development, including inconsistent biomarker collection, site-to-site variation, protocol deviations, enrolment constraints and the interpretation of emerging safety findings. Experienced clinical physicians can help connect central programme strategy with the realities faced by investigators and trial sites.
Why does ELIMINATE-B create an unusually complex clinical and safety-management challenge?
PBGENE-HBV is being evaluated in the first-in-human ELIMINATE-B study as an investigational treatment for chronic hepatitis B. Precision BioSciences is attempting to use ARCUS nucleases delivered through lipid nanoparticles to target covalently closed circular DNA, or cccDNA, which acts as a persistent source of hepatitis B viral replication.
At the European Association for the Study of the Liver Congress in May 2026, the company reported data from 16 patients who had received 38 administrations across five cohorts. Precision BioSciences said biopsy analyses showed a tenfold reduction in cccDNA-derived transcripts following two administrations at a 0.4 milligram-per-kilogram dose, while editing was also observed in the small amount of remaining cccDNA. The findings were company-reported, early-stage results from a limited dataset and should not be treated as evidence of a clinical cure.
The company also reported durable loss of detectable pregenomic RNA in six patients who had measurable levels before treatment and hepatitis B surface antigen reductions in all 15 evaluable patients. These observations strengthen the proposed mechanism of action, but the trial has not yet established whether the biomarker changes will permit patients to discontinue nucleoside analogue therapy without virological relapse. That withdrawal step is likely to become one of the most important tests of the programme.
Safety management remains equally important. Precision BioSciences reported infusion-related reactions, reversible elevations in liver enzymes and Grade 3 hypotension during dose escalation. One patient in the highest-dose cohort experienced two serious adverse events after a second lipid nanoparticle administration, one of which was considered treatment-related and associated with hypotension. The company subsequently introduced measures including slower infusion and increased steroid dosing and reported no further Grade 3 hypotension or severe lipid nanoparticle-related liver-enzyme abnormalities among doses administered under the mitigation protocol at the disclosed cutoff.
The next phase is not simply a matter of enrolling more patients. Precision BioSciences must select a dose and administration schedule that produces meaningful and durable antiviral effects without creating an unacceptable burden from repeat dosing. Additional biopsy evidence, longer biomarker follow-up and a defensible protocol for antiviral withdrawal will be required before the programme’s curative ambition can be assessed more rigorously.
How is FUNCTION-DMD changing the company’s clinical and organisational workload?
PBGENE-DMD is entering an even earlier stage of human evaluation. The investigational programme is designed to use two ARCUS nucleases delivered in a single adeno-associated virus vector to remove exons 45 through 55 of the dystrophin gene. Precision BioSciences estimates that the approach could be relevant to mutations affecting a substantial proportion of patients with Duchenne muscular dystrophy, although clinical benefit has not yet been demonstrated.
The U.S. Food and Drug Administration allowed the Phase 1/2a FUNCTION-DMD study to proceed in February 2026, and PBGENE-DMD subsequently received Fast Track designation. These regulatory developments permit and may facilitate clinical development, but neither decision represents approval or evidence that the treatment is effective.
Arkansas Children’s Hospital became the first activated study site in April, with screening and enrolment opened for eligible patients. The clinical-trial registry describes FUNCTION-DMD as an open-label, multicentre study expected to enrol up to 18 male participants. It will evaluate the safety, tolerability and preliminary efficacy of a single intravenous administration, accompanied by an immunomodulatory regimen intended to reduce immune-mediated risks.
Precision BioSciences has previously indicated that initial data from multiple patients could become available by the end of 2026. That timeline remains an expectation rather than a confirmed outcome, and the registry lists estimated primary completion in 2029. Early muscle-biopsy findings on near full-length dystrophin expression could provide an important biological signal, but functional outcomes and long-term safety will require substantially more follow-up.
The FUNCTION-DMD programme therefore adds considerable organisational complexity before it adds clinical certainty. Paediatric enrolment, vector dosing, immunomodulation, muscle biopsies and extended monitoring all require careful coordination. Even minor delays at individual sites could affect the timing of a very small early dataset, making specialised medical leadership and disciplined operational oversight particularly valuable.
What does Precision BioSciences’ cash position reveal about the timing of the changes?
Precision BioSciences reported $99.4 million in cash and cash equivalents at March 31, 2026, together with $26.5 million in restricted cash. Management said its existing resources, operating discipline and access to an at-the-market equity facility were expected to finance operating requirements and planned PBGENE-HBV and PBGENE-DMD data milestones through 2028.
The company recorded a first-quarter net loss of $18.4 million. Research and development expenses were $13.1 million, while general and administrative expenses declined to $6.8 million. Spending directly attributed to PBGENE-DMD increased as Precision BioSciences initiated institutional-review and trial-site activities, illustrating how costs can shift rapidly when a programme enters human development.
The runway provides time, but it does not eliminate financing risk. The company’s estimate incorporates continued cost control and potential availability under its equity facility. Clinical expansion, additional sites, manufacturing requirements or unexpected safety work could change projected spending. The appointment of Tanna as CFO places financial reporting and investor relations under an executive who has already been involved in communicating the company’s strategy and clinical milestones.
That continuity may reduce transition risk, although Tanna will now be judged on a broader set of responsibilities. Investors will expect transparency around cash consumption, trial timelines and any use of the at-the-market programme. In development-stage biotechnology, a cash runway is most valuable when it reaches a decisive dataset. Simply extending operations without resolving the central clinical questions would carry far less strategic value.
How should investors interpret the DTIL share-price response and current sentiment?
Precision BioSciences shares traded near $7.59 during the July 27 session, up about 4.1% intraday. That level was approximately 3% above the July 20 closing price of $7.36, but roughly 4% below the June 29 close of $7.92, indicating that the stock remained volatile rather than establishing a clear directional response to the management announcement.
The stock had recently traded within a wide 52-week range of approximately $3.53 to $9.62. Precision BioSciences was also added to the Russell 2000 Index following the June 2026 reconstitution, potentially increasing its visibility among index-linked and institutional investors. Index inclusion may support trading activity, but it does not alter the scientific or financial risks attached to the pipeline.
The leadership change is best viewed as an incremental operational signal rather than a standalone value-inflection event. Market sentiment will continue to be governed primarily by ELIMINATE-B dose optimisation, the durability and clinical relevance of hepatitis B biomarker changes, FUNCTION-DMD enrolment and initial human data, and the company’s ability to preserve its cash runway while advancing both programmes.
Which milestones will show whether the leadership reorganisation is working?
The reorganisation will ultimately be evaluated through execution rather than titles. For PBGENE-HBV, the important measures include continued enrolment, additional biopsy evidence, sustained biomarker responses, the safety profile under the revised infusion protocol and selection of a dose and schedule for Part 2. Progress toward a scientifically and ethically defensible nucleoside analogue withdrawal framework would represent a particularly important development.
For PBGENE-DMD, the near-term tests are successful patient dosing, management of immune and vector-related risks, collection of interpretable muscle-biopsy data and evidence that study sites can enrol a narrowly defined paediatric population. Initial dystrophin-expression findings could influence sentiment, but they will need to be interpreted alongside dose, tissue distribution, safety and eventually functional outcomes.
Precision BioSciences has created an executive structure intended to support two programmes that are moving at different speeds and present very different clinical challenges. The new structure may improve accountability across science, development, finance and external engagement. Whether it creates value will depend on something less glamorous than executive titles: delivering reliable clinical data, responding quickly to emerging risks and ensuring that available capital carries both programmes to milestones capable of changing their probability of success.
